{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T19:46:18Z","timestamp":1785527178852,"version":"3.56.0"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T00:00:00Z","timestamp":1779840000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T00:00:00Z","timestamp":1779840000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82171975"],"award-info":[{"award-number":["82171975"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82572319"],"award-info":[{"award-number":["82572319"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003399","name":"Science and Technology Commission of Shanghai Municipality","doi-asserted-by":"publisher","award":["25TS1405600"],"award-info":[{"award-number":["25TS1405600"]}],"id":[{"id":"10.13039\/501100003399","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010229","name":"Natural Science Foundation of Tianjin Municipal Science and Technology Commission","doi-asserted-by":"publisher","award":["23ZR1439600"],"award-info":[{"award-number":["23ZR1439600"]}],"id":[{"id":"10.13039\/501100010229","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002858","name":"China Postdoctoral Science Foundation","doi-asserted-by":"publisher","award":["2024M762244"],"award-info":[{"award-number":["2024M762244"]}],"id":[{"id":"10.13039\/501100002858","id-type":"DOI","asserted-by":"publisher"}]},{"name":"the PostDoctor Research Fund of West China Hospital, Sichuan University","award":["2025HXBH087"],"award-info":[{"award-number":["2025HXBH087"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Nucl Med Mol Imaging"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1007\/s00259-026-07959-3","type":"journal-article","created":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T01:33:41Z","timestamp":1779845621000},"page":"5921-5936","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Optimized PET\/CT response assessment for prognostic stratification compared with Lugano criteria in extranodal NK\/T-Cell lymphoma"],"prefix":"10.1007","volume":"53","author":[{"given":"Xinyu","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaojuan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zitong","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinyun","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pengpeng","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chong","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Miao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0493-2062","authenticated-orcid":false,"given":"Biao","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,27]]},"reference":[{"key":"7959_CR1","doi-asserted-by":"publisher","first-page":"2460","DOI":"10.1038\/s41375-021-01313-2","volume":"35","author":"H Wang","year":"2021","unstructured":"Wang H, Fu B-b, Gale RP, Liang Y. NK-\/T-cell lymphomas. Leukemia. 2021;35:2460\u20138. https:\/\/doi.org\/10.1038\/s41375-021-01313-2.","journal-title":"Leukemia"},{"key":"7959_CR2","doi-asserted-by":"publisher","unstructured":"Tse E, Kwong Y-L. The diagnosis and management of NK\/T-cell lymphomas. J Hematol Oncol. 2017;10. https:\/\/doi.org\/10.1186\/s13045-017-0452-9.","DOI":"10.1186\/s13045-017-0452-9"},{"key":"7959_CR3","doi-asserted-by":"publisher","unstructured":"Tse E, Zhao W-L, Xiong J, Kwong Y-L. How we treat NK\/T-cell lymphomas. J Hematol Oncol. 2022;15. https:\/\/doi.org\/10.1186\/s13045-022-01293-5.","DOI":"10.1186\/s13045-022-01293-5"},{"key":"7959_CR4","doi-asserted-by":"publisher","first-page":"2528","DOI":"10.1182\/blood-2017-12-791418","volume":"131","author":"M Yamaguchi","year":"2018","unstructured":"Yamaguchi M, Suzuki R, Oguchi M. Advances in the treatment of extranodal NK\/T-cell lymphoma, nasal type. Blood. 2018;131:2528\u201340. https:\/\/doi.org\/10.1182\/blood-2017-12-791418.","journal-title":"Blood"},{"key":"7959_CR5","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1200\/JOP.18.00719","volume":"15","author":"PB Allen","year":"2019","unstructured":"Allen PB, Lechowicz MJ. Management of NK\/T-Cell Lymphoma, Nasal Type. J Oncol Pract. 2019;15:513\u201320. https:\/\/doi.org\/10.1200\/JOP.18.00719.","journal-title":"J Oncol Pract"},{"key":"7959_CR6","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1016\/S1470-2045(15)00533-1","volume":"17","author":"SJ Kim","year":"2016","unstructured":"Kim SJ, Yoon DH, Jaccard A, Chng WJ, Lim ST, Hong H, et al. A prognostic index for natural killer cell lymphoma after non-anthracycline-based treatment: a multicentre, retrospective analysis. Lancet Oncol. 2016;17:389\u2013400. https:\/\/doi.org\/10.1016\/S1470-2045(15)00533-1.","journal-title":"Lancet Oncol"},{"key":"7959_CR7","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1038\/s41392-024-01782-8","volume":"9","author":"J Xiong","year":"2024","unstructured":"Xiong J, Cheng S, Gao X, Yu SH, Dai YT, Huang XY, et al. Anti-metabolic agent pegaspargase plus PD-1 antibody sintilimab for first-line treatment in advanced natural killer T cell lymphoma. Signal Transduct Target Ther. 2024;9:62. https:\/\/doi.org\/10.1038\/s41392-024-01782-8.","journal-title":"Signal Transduct Target Ther"},{"key":"7959_CR8","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1038\/s41392-021-00768-0","volume":"6","author":"R Tao","year":"2021","unstructured":"Tao R, Fan L, Song Y, Hu Y, Zhang W, Wang Y, et al. Sintilimab for relapsed\/refractory extranodal NK\/T cell lymphoma: a multicenter, single-arm, phase 2 trial (ORIENT-4). Signal Transduct Target Ther. 2021;6:365. https:\/\/doi.org\/10.1038\/s41392-021-00768-0.","journal-title":"Signal Transduct Target Ther"},{"key":"7959_CR9","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1038\/s41392-024-01825-0","volume":"9","author":"Y Gao","year":"2024","unstructured":"Gao Y, He H, Li X, Zhang L, Xu W, Feng R, et al. Sintilimab (anti-PD-1 antibody) plus chidamide (histone deacetylase inhibitor) in relapsed or refractory extranodal natural killer T-cell lymphoma (SCENT): a phase Ib\/II study. Signal Transduct Target Ther. 2024;9:121. https:\/\/doi.org\/10.1038\/s41392-024-01825-0.","journal-title":"Signal Transduct Target Ther"},{"key":"7959_CR10","doi-asserted-by":"publisher","first-page":"e336","DOI":"10.1016\/S2352-3026(24)00066-8","volume":"11","author":"XP Tian","year":"2024","unstructured":"Tian XP, Cai J, Xia Y, Zhang YC, Wang L, Liu PP, et al. First-line sintilimab with pegaspargase, gemcitabine, and oxaliplatin in advanced extranodal natural killer\/T cell lymphoma (SPIRIT): a multicentre, single-arm, phase 2 trial. Lancet Haematol. 2024;11:e336\u201344. https:\/\/doi.org\/10.1016\/S2352-3026(24)00066-8.","journal-title":"Lancet Haematol"},{"key":"7959_CR11","doi-asserted-by":"publisher","first-page":"94","DOI":"10.3760\/cma.j.cn321828-20240924-00333","volume":"45","author":"JZJ Wang","year":"2025","unstructured":"Wang JZJ, Qiao WL. Clinical practice guideline of PET\/CT and PET\/MR in lymphoma (2025 edition). Chin Soc Nuclear Med. 2025;45:94\u2013104. https:\/\/doi.org\/10.3760\/cma.j.cn321828-20240924-00333.","journal-title":"Chin Soc Nuclear Med"},{"key":"7959_CR12","doi-asserted-by":"publisher","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","volume":"32","author":"BD Cheson","year":"2014","unstructured":"Cheson BD, Fisher RI, Barrington SF, Cavalli F, Schwartz LH, Zucca E, et al. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol. 2014;32:3059\u201368. https:\/\/doi.org\/10.1200\/JCO.2013.54.8800.","journal-title":"J Clin Oncol"},{"key":"7959_CR13","unstructured":"Lymphomas T-C. Version 1.2025. NCCN Clinical Practice Guidelines in Oncology. National Comprehensive Cancer Network; 2025."},{"key":"7959_CR14","doi-asserted-by":"publisher","first-page":"3048","DOI":"10.1200\/jco.2013.53.5229","volume":"32","author":"SF Barrington","year":"2014","unstructured":"Barrington SF, Mikhaeel NG, Kostakoglu L, Meignan M, Hutchings M, M\u00fceller SP, et al Role of imaging in the staging and response assessment of lymphoma: consensus of the International Conference on Malignant Lymphomas Imaging Working Group. J Clin Oncol. 2014;32:3048\u201358. https:\/\/doi.org\/10.1200\/jco.2013.53.5229.","journal-title":"J Clin Oncol"},{"key":"7959_CR15","doi-asserted-by":"publisher","first-page":"683","DOI":"10.2967\/jnumed.112.110890","volume":"54","author":"A Biggi","year":"2013","unstructured":"Biggi A, Gallamini A, Chauvie S, Hutchings M, Kostakoglu L, Gregianin M, et al. International validation study for interim PET in ABVD-treated, advanced-stage hodgkin lymphoma: interpretation criteria and concordance rate among reviewers. J Nucl Med. 2013;54:683\u201390. https:\/\/doi.org\/10.2967\/jnumed.112.110890.","journal-title":"J Nucl Med"},{"key":"7959_CR16","doi-asserted-by":"publisher","first-page":"911","DOI":"10.2967\/jnumed.113.131946","volume":"55","author":"PL Khong","year":"2014","unstructured":"Khong PL, Huang B, Lee EY, Chan WK, Kwong YL. Midtreatment 18F-FDG PET\/CT Scan for Early Response Assessment of SMILE Therapy in Natural Killer\/T-Cell Lymphoma: A Prospective Study from a Single Center. J Nucl Med. 2014;55:911\u20136. https:\/\/doi.org\/10.2967\/jnumed.113.131946.","journal-title":"J Nucl Med"},{"key":"7959_CR17","doi-asserted-by":"publisher","first-page":"1220","DOI":"10.21037\/qims-20-620","volume":"11","author":"X Chen","year":"2021","unstructured":"Chen X, Zhao S, Wang H, Fu C, Tian R, Zou L. Assessment of the prognostic value of interim fluorodeoxyglucose positron emission tomography\/computed tomography in nasal-type extranodal natural killer\/T-cell lymphoma. Quant Imaging Med Surg. 2021;11:1220\u201333. https:\/\/doi.org\/10.21037\/qims-20-620.","journal-title":"Quant Imaging Med Surg"},{"key":"7959_CR18","doi-asserted-by":"publisher","first-page":"2489","DOI":"10.1182\/blood-2016-05-718528","volume":"128","author":"BD Cheson","year":"2016","unstructured":"Cheson BD, Ansell S, Schwartz L, Gordon LI, Advani R, Jacene HA, et al. Refinement of the Lugano Classification lymphoma response criteria in the era of immunomodulatory therapy. Blood. 2016;128:2489\u201396. https:\/\/doi.org\/10.1182\/blood-2016-05-718528.","journal-title":"Blood"},{"key":"7959_CR19","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1007\/s12149-021-01598-4","volume":"35","author":"HL Huang","year":"2021","unstructured":"Huang HL, Ngam PI, Tan KM, Ng DCE, Lim ST, Chan JY. The exact Deauville score, NABS score and high SUVmax predicts outcome in extranodal natural killer\/T-cell lymphoma. Ann Nucl Med. 2021;35:557\u201368. https:\/\/doi.org\/10.1007\/s12149-021-01598-4.","journal-title":"Ann Nucl Med"},{"key":"7959_CR20","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1097\/RLU.0000000000000892","volume":"40","author":"C Jiang","year":"2015","unstructured":"Jiang C, Su M, Kosik RO, Zou L, Jiang M, Tian R. The Deauville 5-Point Scale Improves the Prognostic Value of Interim FDG PET\/CT in Extranodal Natural Killer\/T-Cell Lymphoma. Clin Nucl Med. 2015;40:767\u201373. https:\/\/doi.org\/10.1097\/RLU.0000000000000892.","journal-title":"Clin Nucl Med"},{"key":"7959_CR21","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1097\/MNM.0000000000000731","volume":"38","author":"C Jiang","year":"2017","unstructured":"Jiang C, Liu J, Li L, Kosik RO, Su M, Zou L, Tian R. Predictive approaches for post-therapy PET\/CT in patients with extranodal natural killer\/T-cell lymphoma: a retrospective study. Nucl Med Commun. 2017;38:937\u201347. https:\/\/doi.org\/10.1097\/MNM.0000000000000731.","journal-title":"Nucl Med Commun"},{"key":"7959_CR22","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.1007\/s00277-021-04466-3","volume":"100","author":"P Xu","year":"2021","unstructured":"Xu P, Guo R, You J, Cheng S, Li J, Zhong H, et al. Dynamic evaluation of the prognostic value of (18)F-FDG PET\/CT in extranodal NK\/T-cell lymphoma, nasal type. Ann Hematol. 2021;100:1039\u201347. https:\/\/doi.org\/10.1007\/s00277-021-04466-3.","journal-title":"Ann Hematol"},{"key":"7959_CR23","doi-asserted-by":"publisher","first-page":"3377","DOI":"10.1007\/s00277-025-06420-z","volume":"104","author":"L Li","year":"2025","unstructured":"Li L, Cui F, Tian R, Jiang M, Zou L, Li X, Su M. New FDG-PET\/CT interpretation criteria (Huaxi criteria) for response assessment in patients with nasal-type extranodal NK\/T-cell lymphoma: development and validation. Ann Hematol. 2025;104:3377\u201387. https:\/\/doi.org\/10.1007\/s00277-025-06420-z.","journal-title":"Ann Hematol"},{"key":"7959_CR24","doi-asserted-by":"publisher","first-page":"1719","DOI":"10.2147\/dddt.S136988","volume":"11","author":"RL Van Heertum","year":"2017","unstructured":"Van Heertum RL, Scarimbolo R, Wolodzko JG, Klencke B, Messmann R, Tunc F, et al. Lugano 2014 criteria for assessing FDG-PET\/CT in lymphoma: an operational approach for clinical trials. Drug Des Devel Ther. 2017;11:1719\u201328. https:\/\/doi.org\/10.2147\/dddt.S136988.","journal-title":"Drug Des Devel Ther"},{"issue":"Suppl 1","key":"7959_CR25","doi-asserted-by":"publisher","first-page":"s122","DOI":"10.2967\/jnumed.108.057307","volume":"50","author":"RL Wahl","year":"2009","unstructured":"Wahl RL, Jacene H, Kasamon Y, Lodge MA. From RECIST to PERCIST: Evolving Considerations for PET response criteria in solid tumors. J Nucl Med. 2009;50(Suppl 1):s122\u201350. https:\/\/doi.org\/10.2967\/jnumed.108.057307.","journal-title":"J Nucl Med"},{"key":"7959_CR26","doi-asserted-by":"publisher","first-page":"3927","DOI":"10.1002\/sim.2427","volume":"24","author":"L Antolini","year":"2005","unstructured":"Antolini L, Boracchi P, Biganzoli E. A time-dependent discrimination index for survival data. Stat Med. 2005;24:3927\u201344. https:\/\/doi.org\/10.1002\/sim.2427.","journal-title":"Stat Med"},{"key":"7959_CR27","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.1002\/ajh.25878","volume":"95","author":"SN Qi","year":"2020","unstructured":"Qi SN, Yang Y, Zhang YJ, Huang HQ, Wang Y, He X, et al. Risk-based, response-adapted therapy for early-stage extranodal nasal-type NK\/T-cell lymphoma in the modern chemotherapy era: A China Lymphoma Collaborative Group study. Am J Hematol. 2020;95:1047\u201356. https:\/\/doi.org\/10.1002\/ajh.25878.","journal-title":"Am J Hematol"},{"key":"7959_CR28","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1007\/s00428-016-2011-0","volume":"469","author":"WY Kim","year":"2016","unstructured":"Kim WY, Jung HY, Nam SJ, Kim TM, Heo DS, Kim CW, Jeon YK. Expression of programmed cell death ligand 1 (PD-L1) in advanced stage EBV-associated extranodal NK\/T cell lymphoma is associated with better prognosis. Virchows Arch. 2016;469:581\u201390. https:\/\/doi.org\/10.1007\/s00428-016-2011-0.","journal-title":"Virchows Arch"}],"container-title":["European Journal of Nuclear Medicine and Molecular Imaging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-026-07959-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00259-026-07959-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-026-07959-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T18:09:43Z","timestamp":1785521383000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00259-026-07959-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,27]]},"references-count":28,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["7959"],"URL":"https:\/\/doi.org\/10.1007\/s00259-026-07959-3","relation":{},"ISSN":["1619-7070","1619-7089"],"issn-type":[{"value":"1619-7070","type":"print"},{"value":"1619-7089","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,27]]},"assertion":[{"value":"4 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. This article does not contain any studies with animals performed by any of the authors. The retrospective study protocol was approved by the ethics committees of Ruijin Hospital, Shanghai Jiao Tong University School of Medicine and West China Hospital, Sichuan University. For the nature of retrospective study, written informed consent was waived.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Biao Li is an editor of European Journal of Nuclear Medicine and Molecular Imaging. No other competing interests are declared.","order":2,"name":"Ethics","label":"Competing Interests","group":{"name":"EthicsHeading","label":"Declarations"}}]}}